Today: May 26, 2018, 12:18 pm
  
Health

Singapore eDevelopment Subsidiary Initiates Research on New Universal Therapeutic Drug Platform

Singapore eDevelopment Subsidiary Initiates Research on New Universal Therapeutic Drug Platform
PR-Inside.com: 2017-05-22 13:40:15
- Nobel Prize nominee Daryl Thompson to lead research, conducted by Global BioLife Inc., supported by Charles River Laboratories

- Six month target for validating lab data, twelve month target for completion of platform

SINGAPORE, May 22, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd ("SeD"), through subsidiary Global BioLife Inc. ("Global BioLife"), has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Mr Daryl Thompson.


SGX-listed SeD (SP:SGE) said Mr Thompson would leverage his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.

Mr Thompson will lead the research, to be conducted by Global BioLife, in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD's wholly-owned subsidiary, Global BioMedical Inc. The remaining stake in Global BioLife is held in equal proportions by Mr Thompson's GRDG Sciences LLC and ASX-listed Holista CollTech Limited.

Mr Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world's deadliest diseases. Mr Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.

Global BioLife has engaged NYSE-listed Charles River Laboratories International, Inc., which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Mr Thompson said, "We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available."

"Global BioLife recognizes the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, Global BioLife Director and CEO. Dr Tang has a Ph.D. in Chemical Engineering and was selected as National Distinguished Expert in China's Thousand Talents Plan in 2012.

GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA by Mr Thompson, a natural products scientist. GRDG Sciences works with multiple global institutions such as Charles River. Holista CollTech Ltd is a research-driven biotech company that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. It is dedicated to delivering first-class natural ingredients and wellness products (www.holista.com).

About Singapore eDevelopment Limited

Incorporated on 9 September 2009, and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010 (SP: SGE; SINE), Singapore eDevelopment is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.

Issued on behalf of the Company:

WeR1 Consultants Pte Ltd

Mr Ian Lau

E: ianlau@wer1.net

T: +65 6737 4844

Singapore 048693

Topic: General Announcement

Sectors: Investors/Exchanges, Daily Finance, BioTech, HealthCare, Alternatives

www.acnnewswire.com

From the Asia Corporate News Network

Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Press Information


Published by
ACN Newswire
+65 6304 8926
e-mail
www.acnnewswire.com



# 633 Words
Related Articles
 
More From Health
Daring to Believe- A Memoir of a [..]
Amy Gray-Cunningham, Author and Living Kidney Donor Daring to Believe: A Memoir of a Living Kidney Donor PRESS RELEASE FOR [..]
Cystic Fibrosis: Disease Insights and Market Forecasts [..]
“Cystic Fibrosis: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical [..]
Chamomile Tea Benefits: Shown in Studies for [..]
Chamomile flowers are a member of the daisy family with their bright gold cones shining in the center of white [..]
Pharmascroll launches Market intelligence reports on [..]
Pharmascroll, a Pharmaceutical market research and business consulting firm, would be offering Monthly Market Intelligence reports [..]
PPMS and SPMS: Epidemiology and Market Forecasts [..]
Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.